The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120
Open accessAbstract
The Thai Phase III clinical trial (RV144) showed modest efficacy in preventing HIV-1 acquisition. Plasma collected from HIV-1-uninfected trial participants completing all injections with ALVAC-HIV (vCP1521) prime and AIDSVAX B/E boost were tested for antibody responses against HIV-1 gp120 envelope (Env). Peptide microarray analysis from six HIV-1 subtypes and group M consensus showed that vaccination induced antibody responses to the second variable (V2) loop of gp120 of multiple subtypes. We further evaluated V2 responses by ELISA and surface plasmon resonance using cyclic (Cyc) and linear V2 loop peptides. Thirty-one of 32 vaccine recipients tested (97%) had antibody responses against Cyc V2 at 2 weeks postimmunization with a reciprocal geometric mean titer (GMT) of 1100 (range: 200-3200). The frequency of detecting plasma V2 antibodies declined to 19% at 28 weeks post-last injection (GMT: 110, range: 100-200). Antibody responses targeted the mid-region of the V2 loop that contains conserved epitopes and has the amino acid sequence KQKVHALFYKLDIVPI (HXB2 Numbering sequence 169-184). Valine at position 172 was critical for antibody binding. The frequency of V3 responses at 2 weeks postimmunization was modest (18/32, 56%) with a GMT of 185 (range: 100-800). In contrast, naturally infected HIV-1 individuals had a lower frequency of antibody responses to V2 (10/20, 50%; p=0.003) and a higher frequency of responses to V3 (19/20, 95%), with GMTs of 400 (range: 100-3200) and 3570 (range: 200-12,800), respectively. RV144 vaccination induced antibodies that targeted a region of the V2 loop that contains conserved epitopes. Early HIV-1 transmission events involve V2 loop interactions, raising the possibility that anti-V2 antibodies in RV144 may have contributed to viral inhibition.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationBarnett, S. W., Burke, B., Sun, Y., Kan, E., Legg, H., Lian, Y., Bost, K., Zhou, F., Goodsell, A., zur Megede, J., et al. (2010) · Journal of Virology · doi:10.1128/jvi.02533-09 · Cited by 82
Cited by
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9
McLellan, J. S., Pancera, M., Carrico, C., Gorman, J., Julien, J.-P., Khayat, R., Louder, R., Pejchal, R., Sastry, M., Dai, K., et al. (2011) · Nature · doi:10.1038/nature10696 · Cited by 830
Self-citationYates, N. L., Liao, H.-X., Fong, Y., deCamp, A., Vandergrift, N. A., Williams, W. T., Alam, S. M., Ferrari, G., Yang, Z.-Y., Seaton, K. E., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007730 · Cited by 450
Self-citationChung, A. W., Ghebremichael, M., Robinson, H., Brown, E., Choi, I., Lane, S., Dugast, A.-S., Schoen, M. K., Rolland, M., Suscovich, T. J., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007736 · Cited by 406
Self-citationLiao, H.-X., Bonsignori, M., Alam, S. M., McLellan, J. S., Tomaras, G. D., Moody, M. A., Kozink, D. M., Hwang, K.-K., Chen, X., Tsao, C.-Y., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.11.011 · Cited by 377
Self-citationZolla-Pazner, S., deCamp, A., Gilbert, P. B., Williams, C., Yates, N. L., Williams, W. T., Howington, R., Fong, Y., Morris, D. E., Soderberg, K. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087572 · Cited by 267
Self-citation
Metadata
- Authors
- Karasavvas, N., Billings, E., Rao, M., Williams, C., Zolla-Pazner, S., Bailer, R. T., Koup, R. A., Madnote, S., Arworn, D., Shen, X., Tomaras, G. D., Currier, J. R., Jiang, M., Magaret, C., Andrews, C., Gottardo, R., Gilbert, P., Cardozo, T. J., Rerks-Ngarm, S., Nitayaphan, S., Pitisuttithum, P., Kaewkungwal, J., Paris, R., Greene, K., Gao, H., Gurunathan, S., Tartaglia, J., Sinangil, F., Korber, B. T., Montefiori, D. C., Mascola, J. R., Robb, M. L., Haynes, B. F., Ngauy, V., Michael, N. L., Kim, J. H., & de Souza, F. T. M. T. C.
- Venue
- AIDS Research and Human Retroviruses
- Publisher
- SAGE Publications
- Published
- 2012-11
- Volume
- 28
- Issue
- 11
- Pages
- 1444-1457
- ISSN
- 0889-2229 (ISSN-L)
- 1931-8405
- OpenAlex
- W2065353103
- Cited by
- 211
- References
- 2
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. https://app.cochat.ai/papers/10.1089/aid.2012.0103
- The paper
- Karasavvas, N., Billings, E., Rao, M., Williams, C., Zolla-Pazner, S., Bailer, R. T., Koup, R. A., Madnote, S., Arworn, D., Shen, X., Tomaras, G. D., Currier, J. R., Jiang, M., Magaret, C., Andrews, C., Gottardo, R., Gilbert, P., Cardozo, T. J., Rerks-Ngarm, S., . . . de Souza, F. T. M. T. C. (2012). The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. AIDS Research and Human Retroviruses. https://doi.org/10.1089/aid.2012.0103
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.